查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840585

蝦病診斷市場（按技術、診斷方法、應用、最終用戶和疾病類型）—2025-2032 年全球預測

Shrimp Disease Diagnostics Market by Technology, Diagnostic Method, Application, End User, Disease Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，蝦病診斷市場將成長 8.948 億美元，複合年成長率為 8.14%。

主要市場統計數據
基準年2024年 4.781億美元
預計2025年 5.1754億美元
預測年份：2032年 8.948億美元
複合年成長率（%） 8.14%

提供關於診斷情報在保護蝦類水產養殖健康、供應連續性和法規遵從性方面發揮的關鍵作用的權威指導

蝦子病診斷是水產養殖韌性、公共衛生警戒和永續水產品供應鏈的交匯點。隨著集約化蝦類養殖規模不斷擴大以滿足全球蛋白質需求，蝦類養殖業面臨持續且不斷演變的生物威脅，包括病毒、細菌、真菌和寄生蟲。準確及時的診斷可能意味著局部控制和大規模生產損失之間的差異，同時也能影響抗菌藥物管理、生物安全政策和貿易合規性。

診斷工作流程正從傳統的組織病理學和基於培養的微生物學轉向靈敏度更高、週轉速度更快的分子和免疫學方法。實驗室基礎設施涵蓋從集中式參考中心到現場檢測能力的各種類型，相關人員正在尋求能夠平衡速度、特異性、成本和現場穩定性的工具。同時，監管監督和買家對可追溯性的期望也要求檢測方法必須經過驗證，品質系統也必須透明。這些匯聚的力量正在再形成整個價值鏈的投資重點、營運實務和合作研究議程。

技術進步、數位整合和不斷發展的監測如何改變整個蝦類健康系統的診斷途徑和決策

受技術日趨成熟、流行病學變化以及對營運韌性需求的推動，蝦病診斷領域正在發生重大變化。聚合酵素鏈鎖反應(PCR) 和次世代定序等分子方法已從專業實驗室轉向常規應用，從而提高了病原體檢測的靈敏度。同時，恆溫技術和快速免疫檢測正在縮小實驗室檢驗與養殖場決策之間的差距，縮短了養殖戶在疫情急性爆發時的行動時間。

除了技術之外，樣本追蹤、雲端基礎分析和可互通資料標準的數位化平台的整合，正在改變監測資料的產生、匯總以及為政策和實踐提供依據的方式。這些功能支持更細緻的疫情調查和縱向監測，同時結合環境和管理資料集，也能實現預測分析。此外，檢測連接複用和自動化技術的進步，使實驗室能夠在不相應增加人員的情況下擴大通量，從而改變診斷服務提供者之間的服務交付模式和競爭動態。總而言之，這些轉變正在推動整個診斷生態系統的研究投資、監管檢驗途徑和商業性參與重點的重新調整。

關稅變化對診斷供應鏈、採購週期以及蝦類健康管理先進檢測能力的實際影響

諸如關稅調整之類的政策變化將對整個蝦病診斷生態系統產生實際的連鎖反應，影響試劑採購、設備採購和服務交付的經濟效益。關稅上調會增加進口耗材和資本設備的成本，這將迫使實驗室和診斷供應商重新評估其供應鏈，並優先考慮本地和具有關稅抵禦能力的供應商。雖然這種轉變可以鼓勵供應商多元化以及試劑和基本設備的國內生產，但也可能延長依賴複雜全球供應鏈的專業平台的採購週期。

關稅調整導致的採購波動通常會促使診斷服務供應商重新評估定價、合約條款和庫存策略，以保持其水產養殖客戶檢測的連續性。同時，依賴國際試劑和跨國檢體交換的研究合作可能會遭遇行政摩擦，導致其更加重視國內驗證研究和替代檢測方法。對於水產養殖生產者而言，間接影響可能包括高階診斷工具取得管道的變化以及新實驗室能力投入使用的前置作業時間延長，從而可能改變疫情應對時間表和技術創新的採用速度。

將技術、診斷方式、應用、最終用戶和疾病類別與可行的採用選擇聯繫起來的多維細分觀點

了解細分領域可為評估診斷能力和機會的交會點提供實用視角。從技術角度來看，該領域涵蓋免疫檢測和檢測法恒溫環型核酸擴增相符，次世代定序儀酵素結合免疫吸附試驗 (ELISA) 與側流免疫測定和蛋白質印跡法並列為抗體和抗原檢測的不同選擇。應用導向的細分涵蓋從常規監測和篩檢到監測和疫情調查等各種用例，每個用例都需要獨特的效能特徵和操作工作流程。最終用戶類別進一步細化了採用模式，學術和研究機構專注於方法開發和驗證，診斷實驗室優先考慮服務交付和吞吐量，水產養殖場優先考慮與農場管理相結合的快速、可操作的結果。最後，細菌、真菌、寄生蟲和病毒疾病類型的細分決定了檢測的特異性和採樣策略，因為這些病原體的生物學和傳播動力學需要不同的診斷途徑。

這些環節的相互作用決定了投資、培訓和品質保證的重點，從而實現可靠的診斷。例如，選擇多重PCR還是單靶定量PCR，將取決於生產系統中病毒病原體的流行程度和共存情況；而選擇實驗室ELISA還是側流檢測裝置，則需要權衡靈敏度和養殖場易用性。將技術性能與特定應用和最終用戶相匹配的研究和檢驗工作，將提升診斷產品和服務在蝦類健康領域的轉換價值。

生產量、法律規範和檢測能力的地理差異如何影響診斷重點和協作監測結果

區域動態反映了生產強度、法規環境和研究能力，決定了診斷需求、投資重點和協力網路。在美洲，成熟的水產養殖區將日益成長的可追溯性需求與不斷擴大的診斷服務網路結合。這種環境促進了對實驗室自動化、標準化通訊協定和官民合作關係關係的投資，從而加強了監測並支持了出口市場需求。同時，歐洲、中東和非洲地區的管理體制和基礎設施成熟度各不相同，在這些地區，監管協調和統一的檢驗標準對於實現跨境貿易和協調一致的疫情應對至關重要。

亞太地區仍然是全球蝦類養殖的中心，因此也是疾病控制挑戰的集中地。該地區高密度的養殖系統、多樣化的病原體壓力以及蓬勃發展的診斷供應商群體，正在推動分子平台和實用的現場檢測方法的快速應用。在該地區，對培訓、分散檢測能力和本地化檢測驗證的投資尤其重要，因為它們能夠實現快速的養殖決策，並將診斷方法納入生物安全通訊協定。在所有地區，跨境知識交流、統一的數據標準和合作研究聯盟將提高監測的有效性，並支持更具韌性的疾病應對策略。

診斷提供者之間的策略行動和夥伴關係模式將決定整個產業的創新速度、檢驗的嚴謹性和服務的擴充性

活躍於蝦病診斷領域的公司和機構之間的競爭反映了不同的策略模式。一些公司優先考慮平台技術和全球分銷，其他公司則強調服務產品和區域化的「樣本到答案」解決方案，而新參與企業則專注於可攜式恆溫分析和專業測序等利基創新。試劑製造商、設備供應商和診斷實驗室之間的策略夥伴關係有助於加快檢驗的工作流程的上市時間，並分擔監管提交和現場檢驗的負擔。投資於可擴展生產、強大的品質系統和可互通數據解決方案的公司可以支援更大規模的監測項目，並與可追溯性舉措相結合。

此外，研發途徑越來越依賴與學術機構的合作，共同開發檢測方法，並在相關的現場條件下進行嚴格的驗證。此外，將檢測與諮詢和生物安全諮詢相結合的服務型經營模式能夠創造經常性收益來源並深化客戶關係。為了保持競爭力，企業必須在產品創新投資與驗證、法規遵循和客戶教育方面的承諾之間取得平衡，同時也要考慮如何根據不同的區域採購能力和採購環境調整定價和分銷策略。

診斷提供者和水產養殖領導者可以採取的具體策略步驟，以增強韌性、加速採用並使創新與營運需求保持一致

產業領導者應優先建構具有韌性的供應鏈，實現試劑和設備來源多元化，同時投資區域緩衝庫存和製造外包，以降低貿易政策衝擊的影響。加強與區域實驗室和研究機構的合作，將有助於快速檢驗替代檢測方法，並支援旨在提升熟練技術人員能力的培訓計畫。領導者還應加快部署用於樣本追蹤、結果整合和分析的數位基礎設施，將分散的診斷數據轉化為可供生產商和監管機構操作的情報。

在產品方面，企業應推行模組化檢測設計，以便快速重新配置新的或共存的病原體，並檢驗適合現場使用的檢測方案，以維持實驗室級性能。與水產養殖生產商的策略合作有助於將診斷開發與營運工作流程相結合，並啟動先導計畫，以證明疾病預防方面的投資回報。最後，透明的品質保證流程、統一的驗證通訊協定以及參與實驗室間比對研究，可以增強買家信心，支持監管機構的認可，並促進先進診斷方法的廣泛應用。

該分析以嚴格的混合方法研究框架為基礎，結合了專家諮詢、技術性能審查和三段論證據綜合。

這些見解背後的調查方法結合了系統性文獻綜述、結構化訪談和技術績效評估，以確保觀點的平衡和主導。定性研究部分包括諮詢診斷實驗室主任、水產養殖衛生官員、設備供應商和監管顧問，以了解區域營運限制和採用促進因素。補充性二次分析整合了同行評審研究、技術白皮書和公開的監測報告，以提供技術能力和疾病流行情況的圖像。

技術評估包括交叉比較檢測參數，例如靈敏度、特異性、結果產生時間和現場適用性，以及考慮目標地區的監管途徑和驗證要求。數據合成包括協調不同的資訊來源並應用三角測量技術來識別穩健的模式，品質保證步驟包括與領先的斷言專家進行交叉驗證。該研究認知到快速發展的病原體模式所固有的局限性，並建議隨著新的檢驗數據和監管格局的發展定期更新。

簡明摘要強調了有效診斷、跨部門合作和能力建設對於實現蝦類健康永續改善的重要性。

診斷技術是永續蝦類生產的戰略關鍵，它能夠更有針對性地應對疾病威脅，並支持生物安全、貿易和消費者信心。分子平台、快速免疫檢測和數位分析的整合擴展了生產者、實驗室和監管機構可用的實際選擇，而不斷變化的區域動態和政策也持續影響技術的取得和採用途徑。將技術投資與檢驗的性能、營運可行性和監管預期相結合的相關人員將最有能力減輕疫情的影響並提高長期的抵禦能力。

公司必須提供經過驗證且適用的檢測方法，實驗室必須保持嚴格的品質標準，生產商必須將診斷方法納入其日常管理和生物安全實踐。對協作管治、統一標準和能力建設的投資將加速將診斷資訊轉化為對蝦子健康和生產永續性的實際改善。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 基於 CRISPR 的照護現場診斷檢測方法日益普及，可快速檢測蝦病原體
  • 將人工智慧預測分析與蝦場遙測技術結合，以預警疾病爆發
  • 開發一種可同時檢測多種蝦毒和細菌性疾病的多重PCR檢測方法
  • 攜帶式等溫擴增裝置擴大用於養殖場蝦病的現場監測
  • 實施次世代定序平台，實施全面的蝦子病原體監測計劃
  • 推出利用奈米技術快速辨識蝦病原體的手持式生物感測器晶片
  • 擴展物聯網連接的水質感測器和疾病診斷工具，以最佳化蝦子的健康管理

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 蝦子病診斷市場（依技術）

  • 酵素結合免疫吸附試驗
  • 環介導等溫擴增
  • 次世代定序
  • 聚合酵素鏈鎖反應
    • 多重PCR
    • 定量PCR
    • 逆轉錄PCR

9. 蝦子病診斷市場（依診斷方法）

  • 組織病理學診斷
  • 免疫學診斷
    • 酵素結合免疫吸附試驗
    • 側流免疫檢測
    • 蛋白質印跡法
  • 微生物診斷
  • 分子診斷

第10章蝦病診斷市場的應用

  • 監控
  • 疫情調查
  • 調查
  • 篩檢

第 11 章。蝦子病診斷市場（按最終用戶）

  • 學術機構
  • 水產養殖場
  • 診斷實驗室
  • 研究機構

第 12 章蝦病診斷市場（依疾病類型）

  • 細菌性疾病
  • 真菌病
  • 寄生蟲病
  • 病毒性疾病

第13章蝦病診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章蝦病診斷市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 蝦子病診斷市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • PerkinElmer, Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Ceva Sante Animale SA
Product Code: MRR-03023C19E52A

The Shrimp Disease Diagnostics Market is projected to grow by USD 894.80 million at a CAGR of 8.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 478.10 million
Estimated Year [2025] USD 517.54 million
Forecast Year [2032] USD 894.80 million
CAGR (%) 8.14%

An authoritative orientation to the critical role of diagnostic intelligence in safeguarding shrimp aquaculture health, supply continuity, and regulatory compliance

Shrimp disease diagnostics sits at the intersection of aquaculture resilience, public health vigilance, and sustainable seafood supply chains. As intensive shrimp farming expands to meet global protein demand, the industry confronts a persistent and evolving set of biological threats driven by viral, bacterial, fungal, and parasitic agents. Accurate and timely diagnosis determines the difference between localized containment and large-scale production losses, while also shaping antimicrobial stewardship, biosecurity policies, and trade compliance.

Diagnostic workflows have diversified from traditional histopathology and culture-based microbiology toward molecular and immunological approaches that deliver greater sensitivity and faster turnaround. Laboratory infrastructure now ranges from centralized reference centers to on-site testing capabilities, and stakeholders require tools that balance speed, specificity, cost, and field robustness. At the same time, regulatory scrutiny and buyer expectations for traceability demand validated assays and transparent quality systems. These convergent forces are reshaping investment priorities, operational practices, and collaborative research agendas across the value chain.

How technological advances, digital integration, and evolving surveillance practices are reshaping diagnostic pathways and decision-making across shrimp health systems

The diagnostic landscape for shrimp diseases is undergoing transformative shifts driven by technological maturation, shifting epidemiology, and the imperative for operational resilience. Molecular modalities such as polymerase chain reaction variants and next-generation sequencing have moved from specialty labs into routine use, enabling pathogen detection with higher sensitivity and enabling strain-level discrimination that informs targeted interventions. Concurrently, isothermal technologies and rapid immunoassays are closing the gap between laboratory validation and on-farm decision-making, reducing time-to-action for producers facing acute outbreaks.

Beyond technology, integration of digital platforms for sample tracking, cloud-based analytics, and interoperable data standards is changing how surveillance data is generated, aggregated, and translated into policy and practice. These capabilities support more nuanced outbreak investigations and longitudinal monitoring, while also enabling predictive analytics when paired with environmental and management datasets. Moreover, advancements in assay multiplexing and automation are enabling laboratories to scale throughput without proportionally increasing labor, which in turn alters service delivery models and the competitive dynamics among diagnostic providers. Taken together, these shifts recalibrate priorities for research investment, regulatory validation pathways, and commercial engagement across the diagnostic ecosystem.

Real-world repercussions of tariff shifts on diagnostic supply chains, procurement cycles, and access to advanced testing capabilities in shrimp health management

Policy changes such as revised tariff regimes have practical ripple effects across the shrimp disease diagnostics ecosystem, influencing reagent sourcing, instrument procurement, and the economics of service delivery. When tariffs increase costs for imported consumables and capital equipment, laboratories and diagnostic suppliers reassess supply chains and prioritize vendors with local or tariff-resilient footprints. This reorientation can accelerate supplier diversification and incentivize domestic production of reagents and basic instrumentation, but it may also lengthen procurement cycles for specialized platforms that rely on complex global supply chains.

Procurement volatility caused by tariff adjustments often prompts diagnostic service providers to re-evaluate pricing, contract terms, and inventory strategies to preserve continuity of testing for aquaculture clients. In parallel, research collaborations that depend on internationally sourced reagents or cross-border specimen exchange may encounter administrative friction, prompting greater emphasis on in-country validation studies and alternative assay formats. For aquaculture operators, the indirect consequences include shifts in access to high-end diagnostics and longer lead times for commissioning new laboratory capabilities, which can alter outbreak response timelines and the pace at which innovation is adopted.

A multidimensional segmentation perspective that links technologies, diagnostic modalities, applications, end users, and disease classes to practical adoption choices

Understanding segmentation provides a pragmatic lens to evaluate where diagnostic capabilities and commercial opportunities converge. When the technology axis is examined, the field spans conventional immunoassays such as enzyme linked immunosorbent assay alongside nucleic acid amplification methods including loop mediated isothermal amplification and polymerase chain reaction variants, with next generation sequencing offering comprehensive genomic insight; within polymerase chain reaction approaches practitioners distinguish multiplex PCR, quantitative PCR, and reverse transcription PCR according to the needs for throughput, quantitation, and RNA pathogen detection. Diagnostic method distinctions complement this view, encompassing histopathological diagnostics and microbiological culturing alongside molecular diagnostics and immunological approaches where enzyme linked immunosorbent assay sits with lateral flow immunoassay and western blot as differing options for antibody or antigen detection. Application-oriented segmentation frames use cases ranging from routine monitoring and screening to research and outbreak investigation, each demanding specific performance characteristics and operational workflows. End user categories further refine adoption patterns, with academic institutions and research institutes focusing on method development and validation, diagnostic laboratories concentrating on service delivery and throughput, and aquaculture farms prioritizing rapid, actionable results that integrate with on-farm management. Finally, disease type segmentation-spanning bacterial, fungal, parasitic, and viral diseases-dictates assay specificity and sampling strategies, since the biological behaviors and transmission dynamics of these agent classes require distinct diagnostic pathways.

These interlocking segment dimensions drive where investment, training, and quality assurance must be applied to realize reliable diagnostics. For example, decisions around adopting multiplex PCR versus single-target quantitative PCR are informed by the prevalence and co-occurrence of viral pathogens in a production system, while the choice between laboratory-based ELISA and lateral flow devices reflects trade-offs between sensitivity and on-farm usability. Research and validation efforts that align technology performance to specific applications and end users enhance the translational value of diagnostic products and services across the shrimp health landscape.

How geographic differences in production intensity, regulatory frameworks, and laboratory capacity determine diagnostic priorities and collaborative surveillance outcomes

Regional dynamics shape diagnostic needs, investment priorities, and collaborative networks in ways that reflect production intensity, regulatory environments, and research capacity. In the Americas, established aquaculture regions combine growing demand for traceability with expanding diagnostic service networks; this setting favors investments in laboratory automation, standardized protocols, and public-private partnerships that strengthen surveillance and support export market requirements. Meanwhile, Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure maturity, where regulatory alignment and harmonized validation standards are critical to enabling cross-border trade and coordinated outbreak responses, and where capacity-building initiatives often prioritize establishing accredited reference laboratories and harmonized reporting frameworks.

The Asia-Pacific region remains central to global shrimp production and therefore concentrates a large share of disease management challenges; here, high-density farming systems, diverse pathogen pressures, and a thriving diagnostics supplier base drive rapid uptake of both molecular platforms and pragmatic field-ready assays. Investment in training, decentralized testing capabilities, and localized assay validation are particularly important in this region, as they enable faster on-farm decisions and stronger integration of diagnostics into biosecurity protocols. Across all regions, cross-border knowledge exchange, harmonized data standards, and collaborative research consortia amplify the effectiveness of surveillance efforts and support more resilient disease response strategies.

Strategic behaviors and partnership models among diagnostics providers that determine innovation velocity, validation rigor, and service scalability across the industry

Competitive dynamics among firms and institutions active in shrimp disease diagnostics reflect divergent strategic models: some prioritize platform technologies and global distribution, others emphasize service provision and localized sample-to-answer solutions, while emerging entrants focus on niche innovations such as portable isothermal assays or specialized sequencing analytics. Strategic partnerships between reagent manufacturers, instrument suppliers, and diagnostic laboratories accelerate time to market for validated workflows and help distribute the burden of regulatory submission and field validation. Companies that invest in scalable manufacturing, robust quality systems, and interoperable data solutions position themselves to support larger surveillance programs and integrate with traceability initiatives.

Innovation pathways also increasingly rely on alliances with academic and research institutions to co-develop assays and to conduct rigorous validation under relevant field conditions. Furthermore, service-based business models that combine testing with advisory and biosecurity consulting create recurring revenue streams and deepen customer relationships. To remain competitive, organizations must balance investments in product innovation with commitments to validation, regulatory compliance, and customer education, while also considering how to adapt pricing and distribution strategies to diverse regional purchasing capacities and procurement environments.

Concrete strategic steps that diagnostic providers and aquaculture leaders can adopt to strengthen resilience, accelerate adoption, and align innovations with operational needs

Industry leaders should prioritize creating resilient supply chains by diversifying reagent and instrument sourcing while investing in localized buffer stocks and contract manufacturing arrangements to reduce exposure to trade policy shocks. Strengthening ties with regional laboratories and research institutions enables faster validation of alternative assays and supports training programs that expand skilled technical workforce capacity. Leaders should also accelerate the adoption of digital infrastructure for sample tracking, result integration, and analytics to convert dispersed diagnostic data into actionable intelligence for producers and regulators.

On the product side, companies should pursue modular assay designs that allow rapid reconfiguration for new or co-circulating pathogens, and they should validate field-suitable formats that preserve laboratory-level performance. Strategic collaborations with aquaculture producers can help align diagnostic development with operational workflows and create pilot projects that demonstrate return-on-investment in disease prevention. Finally, transparent quality assurance processes, harmonized validation protocols, and participation in inter-laboratory comparison studies will build trust among buyers, support regulatory acceptance, and facilitate wider adoption of advanced diagnostics.

A rigorous mixed-methods research framework blending expert consultations, technical performance review, and triangulated evidence synthesis to underpin the analysis

The research approach underlying these insights combined systematic literature review, structured interviews, and technology performance assessments to ensure a balanced and evidence-driven perspective. The qualitative component included consultations with diagnostic laboratory directors, aquaculture health managers, instrument suppliers, and regulatory advisors to capture operational constraints and adoption drivers across geographies. Complementary secondary analysis synthesized peer-reviewed studies, technical white papers, and publicly available surveillance reports to characterize technology capabilities and disease prevalence contexts.

Technical evaluation involved cross-comparison of assay parameters such as sensitivity, specificity, time-to-result, and field suitability, as well as consideration of regulatory pathways and validation requirements in target regions. Data synthesis applied triangulation methods to reconcile differing sources and identify robust patterns, while quality assurance steps included cross-validation of key claims with subject-matter experts. The study acknowledges limitations inherent to rapidly evolving pathogen landscapes and recommends periodic updates as new validation data and regulatory developments emerge.

A concise synthesis underscoring the centrality of validated diagnostics, cross-sector collaboration, and capacity-building for durable shrimp health outcomes

Diagnostics constitute a strategic linchpin for sustainable shrimp production, enabling more precise responses to disease threats and supporting biosecurity, trade, and consumer confidence. The convergence of molecular platforms, rapid immunoassays, and digital analytics is expanding the practical options available to producers, laboratories, and regulators, while regional dynamics and policy shifts continue to shape access and adoption pathways. Stakeholders who align technology investments with validated performance, operational feasibility, and regulatory expectations will be best positioned to reduce outbreak impacts and improve long-term resilience.

Looking ahead, success will depend on coordinated efforts across the value chain: companies must deliver validated, fit-for-purpose assays; laboratories must uphold rigorous quality standards; and producers must integrate diagnostics into routine management and biosecurity practices. Collaborative governance, harmonized standards, and investments in capacity-building will accelerate the translation of diagnostic intelligence into on-the-ground improvements in shrimp health and production sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of CRISPR-based point-of-care diagnostic assays for shrimp pathogens enabling faster detection
  • 5.2. Integration of AI-powered predictive analytics with shrimp farm telemetry for early disease outbreak alerts
  • 5.3. Development of multiplex PCR assays for simultaneous detection of multiple shrimp viral and bacterial diseases
  • 5.4. Growing use of portable isothermal amplification devices for on-site shrimp disease monitoring at farms
  • 5.5. Implementation of next generation sequencing platforms for comprehensive shrimp pathogen surveillance programs
  • 5.6. Emergence of handheld biosensor chips leveraging nanotechnology for rapid shrimp pathogen identification
  • 5.7. Expansion of IoT-connected water quality sensors coupled with disease diagnostic tools to optimize shrimp health management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shrimp Disease Diagnostics Market, by Technology

  • 8.1. Enzyme Linked Immunosorbent Assay
  • 8.2. Loop Mediated Isothermal Amplification
  • 8.3. Next Generation Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Multiplex PCR
    • 8.4.2. Quantitative PCR
    • 8.4.3. Reverse Transcription PCR

9. Shrimp Disease Diagnostics Market, by Diagnostic Method

  • 9.1. Histopathological Diagnostics
  • 9.2. Immunological Diagnostics
    • 9.2.1. Enzyme Linked Immunosorbent Assay
    • 9.2.2. Lateral Flow Immunoassay
    • 9.2.3. Western Blot
  • 9.3. Microbiological Diagnostics
  • 9.4. Molecular Diagnostics

10. Shrimp Disease Diagnostics Market, by Application

  • 10.1. Monitoring
  • 10.2. Outbreak Investigation
  • 10.3. Research
  • 10.4. Screening

11. Shrimp Disease Diagnostics Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Aquaculture Farms
  • 11.3. Diagnostic Laboratories
  • 11.4. Research Institutes

12. Shrimp Disease Diagnostics Market, by Disease Type

  • 12.1. Bacterial Diseases
  • 12.2. Fungal Diseases
  • 12.3. Parasitic Diseases
  • 12.4. Viral Diseases

13. Shrimp Disease Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shrimp Disease Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shrimp Disease Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific, Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. Abbott Laboratories
    • 16.3.5. PerkinElmer, Inc.
    • 16.3.6. QIAGEN N.V.
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. Zoetis Inc.
    • 16.3.9. Merck & Co., Inc.
    • 16.3.10. Ceva Sante Animale S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SHRIMP DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SHRIMP DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHRIMP DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REVERSE TRANSCRIPTION PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC METHOD, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOG